Toward Precision Prescribing of GLP-1 Receptor Agonists for Glucose Lowering
- 20 October 2026
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (11) , 1941-1943
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Impact of gastric emptying and small intestinal carbohydrate absorption on glycemia in health and diabetes: therapeutic implicationsPhysiological Reviews, 2026
- Genetic predictors of GLP1 receptor agonist weight loss and side effectsNature, 2026
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesNew England Journal of Medicine, 2024
- GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 DiabetesJAMA Network Open, 2024
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trialsThe Lancet Diabetes & Endocrinology, 2022
- Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UKBMJ Open Diabetes Research & Care, 2022
- Type 2 diabetes risk alleles in PAM impact insulin release from human pancreatic β-cellsNature Genetics, 2018
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016
- Activating Mutations in the Gene Encoding the ATP-Sensitive Potassium-Channel Subunit Kir6.2 and Permanent Neonatal DiabetesNew England Journal of Medicine, 2004